LCM
BCRX icon

Landscape Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Landscape Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42,673
Closed -$256K – 752
2023
Q4 		$256K Buy
+42,673
New +$247K 0.02% 614
2023
Q2 		– Sell
-18,705
Closed -$156K – 576
2023
Q1 		$156K Buy
+18,705
New +$180K 0.02% 483

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Landscape Capital Management's BCRX Position: Q1 2024 in Review

Landscape Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2024, closing a stake of 42,673 shares — an estimated $256K sold.

Landscape Capital Management first reported a position in BCRX in Q1 2023 and held it in 2 quarters. The position peaked at $256K in Q4 2023. 238 funds tracked by Wall St. Rank hold BCRX as of Q1 2024.

  • Landscape Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Landscape Capital Management sold 42,673 BioCryst Pharmaceuticals shares in Q1 2024, an estimated $256K.
  • Landscape Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Landscape Capital Management's BioCryst Pharmaceuticals position peaked at $256K in Q4 2023.
  • 238 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2024.

Based on Landscape Capital Management's 13F filing for Q1 2024, filed 9 May 2024.